Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism.

Thromb J · 2025 · PMC12001618 · PMID 40241057

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep = 0.07so close (0.05 < p ≤ 0.1)

Five hours after initial edoxaban administration, the PT in the cancer group was greater than that in the noncancer group, but it did not reach statistical significance (log-transformed PT 2.83 vs. 2.81; Δ0.071, 95% CI [− 0.005, 0.148]; p = 0.07).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.